A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

By 2060, 1 million adults per year will develop dementia, according to a study published in Nature Medicine. Also in the news, chronic cannabis use may lead to chronic illness; Eli Lilly hopes to ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

Some people are microdosing certain weight loss drugs in an attempt to reap some of the drugs' benefits with fewer of their side effects. But doctors specializing in weight loss say that ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...